Fig. 1From: Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker studya Comparison of tumor mutation burden (TMB) in responders and non-responders to combined immunotherapy. b Comparison of tumor mutation burden (TMB) in complete responders, partial responders, and non-responders to combined immunotherapyBack to article page